Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia

Since the introduction of glucocorticoid (GC) replacement therapy, congenital adrenal hyperplasia (CAH) is no longer a fatal disease. The development of neonatal screening programs and the amelioration of GC treatment strategies have improved significantly life expectancy in CAH patients. Thanks to...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbot, Mattia, Mazzeo, Pierluigi, Lazzara, Martina, Ceccato, Filippo, Scaroni, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376294/
https://www.ncbi.nlm.nih.gov/pubmed/35979433
http://dx.doi.org/10.3389/fendo.2022.934675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376294/
https://www.ncbi.nlm.nih.gov/pubmed/35979433
http://dx.doi.org/10.3389/fendo.2022.934675

Ejemplares similares